Brief: Corvus Pharmaceuticals Confirms Initiation of Phase 3 Registrational Study Trial For Soquelitinib In Peripheral T Cell Lymphoma Following Meeting With FDA
06/09/2023 22:58
Sept 6 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS CONFIRMS PLANNED INITIATION OF
SOQUELITINIB (CPI-818) PHASE 3 REGISTRATIONAL CLINICAL TRIAL IN
PERIPHERAL T CELL LYMPHOMA FOLLOWING MEETING WITH FDA
* CORVUS PHARMACEUTICALS INC - PLANS TO INITIATE
SOQUELITINIB
POTENTIALLY REGISTRATIONAL PHASE 3 CLINICAL TRIAL IN Q1 2024
Source text for Eikon: ID:nGNX89DLq7
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental